Pharmaceutical manufacturers of Ezetimibe

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA.

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

Situated in Hyderabad, India, Symed Labs Ltd is a prominent and innovative producer of Active Pharmaceutical Ingredients (APIs) & a comprehensive solution provider for the pharmaceutical sector for chemistry related services. Symed labs has autonomously created processes for more than fifty APIs across various therapeutic categories in the laboratory and upscaled them to plant, as well as vending them to over 600 clients in 30 nations in the regulated and less regulated markets

Indoco Remedies Limited, based in India, is an emerging, fully integrated, research-oriented pharmaceutical firm with a global presence. We manufacture a diverse range of cost-effective, high-quality products in various therapeutic sectors that are widely embraced by healthcare professionals and clients across the globe. The company boasts a robust production infrastructure, a focus on Research & Development, and is uniquely positioned as a preferred collaborator providing comprehensive solutions to pharmaceutical companies marketing generics

Glenmark Life Sciences Limited is a prominent producer and developer of specialized, high-value, non-generic, active pharmaceutical ingredients (APIs) within chronic therapeutic fields such as heart disease, disorders of the central nervous system, pain management, and diabetes. The corporation is progressively offering CDMO services to various multinational and specialized pharmaceutical firms. It maintains a varied collection of over 137 compounds and delivers its merchandise to clients in India, Europe, North America, Latin America, Japan, and other parts of the globe (ROW).

Headquartered in Chandigarh, India, Ind-Swift Laboratories Ltd. today is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration). With regulated 6+ manufacturing sites (including 2 group subsidiaries) in Punjab and Jammu, we cater to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. Today, Ind-Swift Laboratories Ltd. is a significant player in manufacturing APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. We also hold global leadership positions in the Macrolide Antibiotic segment.

We at Raks are dedicated to develop and manufacture active pharmaceutical ingredients and intermediates. We are committed to create value through intellectual property, quality systems and customer relation across the globe. We are research driven company providing cost effective and environmental friendly technologies with safety and quality as primary focus.

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

We have more than 20 years of experience providing a range of contract research, development and manufacturing services across the drug development continuum, with a focus on early-stage discovery and development of new molecular entities (NMEs). Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

Lunan Pharma is a prominent pharmaceutical firm dedicated to enhancing human well-being through the production and promotion of top-quality pharmaceutical products. The company achieved total sales revenues of 1.8 billion dollars in 2020 and is ranked among the top 22 in China.

Tianyu Pharmaceutical, Co., Ltd was established in 1993. It is engaged in the research, development and manufacturing of APIs and advanced intermediates with a registered capitalization of RMB120 million. The company comprises 6 wholly-owned subsidiaries with a total employee population in excess of 2600 and occupying an area of over 470,000 ㎡. Tianyu is recognized as a model high-tech enterprise in Chinas Torch Program. Tianyu is specializing in pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant and anti-asthmatic series. The products are well sold to domestic and overseas markets, winning customer`s recognition and praise.

Hanmi has experienced notable expansion since its establishment in 1973 and has emerged as the most prominent company among pharmaceutical firms in South Korea. We take pride in being recognized as a global frontrunner in the production of high-quality API for cephalosporins, cardiovascular, anti-diabetic, gastrointestinal, and CNS medications. The facilities have undergone inspection and received approval from UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has successfully developed and introduced new combination drugs and a series of IMDs using its patented process

SMS Lifesciences is a prominent participant in APIs/Intermediates production with a robust research and manufacturing team supported by cutting-edge facilities. Originating as a single-facility, single-product manufacturer in 1990, it has expanded into a multi-location group with products spanning various therapeutic segments. In 1997-98, SMS Group was accorded the export house status. Currently, SMS Lifesciences is a publicly listed company with a continuously expanding international and domestic customer base.

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu province, China, Changzhou pharmaceutical Factory has a rich history & Lineage in the pharmaceutical sector. The company was founded in 1949 by (Tan Ruiting) with a registered capital 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of Shanghai Pharma Group. The Chinese business of Changzhou pharmaceutical factory was full fledged sales & marketing organization,Changzhou Pharma is a one of the prominent players in the Chinese pharmaceutical formulations market with a strong foothold across multiple therapies. The company have more than 1500 employees across the country and has earned a reputation amongest the Chinese pharmaceutical companies for providing innovative, comprehensive and complete healthcare solutions. At Changzhou pharmaceutical Factory, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach across US, Europe, the Asia Pacific region and emerging markets. Our high quality manufacturing dedicated facilities for Oncology, Non Oncology, Complex Generics, OTC-Products and sterile injectables, scientific excellence and vast supply chain network to improve access to medicine for patients worldwide. The company mainly involves leading pharmaceutical manufacturer a wide range of key Intermediates, Active pharmaceutical ingredients, Finished Formulations meet with global standards, Changzhou Pharmaceutical Factory it covers an area of 300,000㎡ including R&D, dedicated manufacturing, international marketing office. And we maintain an industry -leading pipeline, composed of numerous complex generics and state owned brands. The company annually brings 800 tons of API's and 3000 millions of Finished dosage forms across the Globe.

Our aim is to become a prominent company in the API and key intermediates industry. Established in 1994, our company is a certified GMP enterprise, specializing in the manufacturing of APIs (Active Pharmaceutical Ingredients), key intermediates of APIs, and fine chemicals. We pride ourselves on delivering high-quality products (APIs and key intermediates) that are meticulously prepared under stringent quality control and exceptional process management. Furthermore, we are a dynamic venture company striving to emerge as a global leader in the generic API industry. Through continuous research and development, we are enhancing our research capabilities and proprietary technology.

Established in the year 2000 as Dongwoo Shintech Co., Ltd., INIST ST has emerged as a pioneer in the advancement of pharmaceutical raw materials and the technology for synthesizing raw materials. Guided by the principles of transformation, innovation, and a passion for life, INIST ST has been engaged in the exploration and production of high-caliber generic raw materials and enhanced drugs through salt modification, commencing with the development of treatments for cerebrovascular diseases and distributing them both nationally and globally. Backed by unwavering trust and expertise, it is utilized as a contrast agent for heart disease and serves as the basis for numerous original active ingredients.